Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 13;12:975408. doi: 10.3389/fonc.2022.975408

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Deng, Yang, Tian, Liu, Sun and Yang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

In vivo efficacy of intratumoral therapy with OX40L mRNA. (A) Timeline for treatment of H22 tumor-bearing mice. (B) Kaplan-Meier analysis of mouse survival after treatment with OX40L-mRNA and non-coding mRNA; log-rank test, p =0.0183. (C) Growth of subcutaneous tumors growth curves (median ± interquartile range [IQR]) of each group treated with OX40L-mRNA and the control. Two-way repeated-measures ANOVA using the Sidak multiple-comparisons test, **p≤ 0.01, ***p≤ 0.001, compared to non-coding mRNA. (D) Images of mice from the two groups at day 37. (E) Tumors; white circle, no tumor. (F) Tumor volume at day 37. Statistical significance was calculated via t test. ***p ≤ 0.001. (G) Tumor weight at day 37. Statistical significance was calculated via t test. ***p≤0.001.